Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2000, p. 1305-1306, Vol. 38, No. 3
Emergence of Serotype G9 Human Rotaviruses in Australia
Received 9 November 1999/Returned for modification 26 November
1999/Accepted 17 December 1999
Rotaviruses are the major cause of severe gastroenteritis in young
children worldwide. The first licensed human rotavirus vaccine, the
rhesus rotavirus-tetravalent vaccine (RRV-TV), incorporated serotype
G1, G2, G3, and G4 specificities, as these have been the four most
common serotypes causing severe disease in children globally over the
last 20 years (7). The RRV-TV has recently been suspended
from routine use because of an association between vaccination and
increased rates of intussusception among vaccine recipients
(1). Recent second-generation (bovine virus-based) vaccines
also include G1 to G4 specificities (2). However, the
increase in reports of other rotavirus serotypes as a cause of severe
diarrhea suggests that future vaccines may need to incorporate additional specificities. Serotype G9 rotaviruses have recently emerged
as important human pathogens in India (9), the United States
(8), Bangladesh (10), Malawi (3), the
United Kingdom (M. Iturriza, J. Green, M. Ramsay, D. Brown, U. Desselberger, and J. J. Gray, Abstr. 18th Ann. Meet. Am. Soc.
Virol., abstr. W43-2, p. 136, 1999; A. D. Steele and W. D. Cubitt, Abstr. 18th Ann. Meet. Am. Soc. Virol, abstr. W43-3, p. 136, 1999), and Nigeria (V. Akran, A. Mbida, J. Mwenda, J. Muyanga, L. Nimzing, J. Nyangao, G. Pennap, D. Steele, A. Trablesi, and S. Tswana,
Abstr. XIth Int. Congr. Virol., abstr. VP25.11, p. 374, 1999). This has
raised interest in the global distribution of this serotype in the
context of the development of effective vaccine formulations.
As part of a national surveillance program, rotavirus-positive fecal
samples collected from children under 5 years of age admitted to the
New Children's Hospital, Sydney, Australia, between June and August
1999 were transported to our laboratory. Routine serotyping was carried
out by enzyme immunoassay (EIA) using neutralizing monoclonal
antibodies (NMAbs) specific for the common serotypes G1 to G4. Thirteen
of 42 samples were found to be nonreactive to these NMAbs.
Rotavirus RNA was purified from feces and subjected to reverse
transcription (RT)-PCR genotyping (5) incorporating primers specific for the common serotypes G1 to G4 and the less-common human
serotypes G8 and G9. Eleven samples (i.e., 26.2% of the 42 tested)
yielded a 304-bp product specific for serotype G9 (Table 1). A partial sequence of the VP7 gene
(which determines G serotype specificity) was determined for one of the
strains (E901 [see below]), and the sequence was used to search the
GenBank database for similar sequences. The best match was with the
prototype G9 Indian strain, 116E, which exhibited 84.5% nucleotide
identity over a 97-bp region. This analysis confirmed the G9 serotype
assignment obtained by PCR. All G9 samples exhibited VP6 subgroup II
specificity.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
FAST-TRACK COMMUNICATION
![]()
TEXT
Top
Text
References
TABLE 1.
Serotype G9 rotaviruses isolated in Sydney, Melbourne,
and Brisbane, Australia, from June to August 1999
Analysis of genomic RNA segments by polyacrylamide gel electrophoresis showed that all samples displayed a "long" RNA migration pattern (electropherotype). However, three distinct electropherotypes were identified: nine isolates displayed an identical pattern (designated E901), while two isolates showed unique patterns (designated E902 and E903) characterized by mobility shifts in RNA segments 5, 7, 8, 9, and 10 (Table 1). Subsequent testing, by RT-PCR, of nonreactive (with respect to serotypes G1 to G4) samples collected from children admitted to the Royal Brisbane Hospital Australia detected one isolate (from July 1999) with G9 specificity and an E901 electropherotype (Table 1). Seven nonreactive samples collected from children admitted to the Royal Children's Hospital, Melbourne, Australia, between June and August 1999 were also typed as G9 by RT-PCR. These samples, which constituted 8.1% of samples collected during this 3-month period, also displayed an E901 electropherotype (Table 1). This demonstrated the dissemination of the E901 strain to these major Australian cities, each separated by at least 600 miles (>700 km). Serotype G9 viruses were not detected among nonreactive samples collected in other Australian cities (Adelaide and Perth) during the same period.
The antigenic properties of the three G9 strains were tested by determining their reactivities with the G9-specific NMAb F45:8 (6). The isolate displaying the E902 electropherotype reacted with F45:8, while variable reactivity was noted for E901. This suggested that the G9 strains exhibited antigenic as well as genetic variation. All strains were tested for their VP4 (P-type) specificity by nested PCR incorporating P-type-specific primers (4) and were found to belong to genotype P[8]. Thus, the features of the Australian G9 strains (subgroup II, long electropherotype, P[8]) were reminiscent of recently described human G9 viruses in the United States and Bangladesh.
Preliminary analysis (using Northern hybridization, EIA, and RT-PCR) of nonreactive rotavirus samples from stored collections has identified G9 viruses in specimens collected in Melbourne (one isolate) and Perth (two isolates) in 1997. Electrophoretic analysis indicated that these strains were different from those detected in 1999. Nevertheless, this suggests that G9 viruses had been circulating, albeit in low numbers, in the Australian community prior to 1999, when they emerged as important causes of severe diarrhea.
In summary, we have detected the first serotype G9 Australian rotavirus isolates and extended the global distribution of this emerging serotype. Analysis of genomic RNA profiles suggested that genetic diversity in circulating strains was evident. Variation in the reactivities of these strains to a G9-specific NMAb also suggested the existence of antigenic diversity. Further studies of historical collections will help to determine when these viruses first appeared in Australia. Molecular studies will determine the extent of genetic variation and the relatedness of these strains to other G9 viruses. Results here and elsewhere will have implications for rotavirus vaccine development. The incorporation of appropriate G (e.g., G9) and P (e.g., P[8]) specificities into candidate human vaccines needs to be considered.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by Commonwealth Department of Health and Aged Care and the Royal Children's Hospital Research Institute.
| |
FOOTNOTES |
|---|
* Phone: 61 3 9345 5060
Fax: 61 3 9345 6240
E-mail: palomboe{at}cryptic.rch.unimelb.edu.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Barnes, G. 1999. Intussusception and rotavirus vaccine. J. Pediatr. Gastroenterol. Nutr. 29:375[Medline]. |
| 2. | Clements-Mann, M. L., M. K. Makhene, J. Mrukowicz, P. F. Wright, Y. Hoshino, K. Midthun, E. Sperber, R. Karron, and A. Z. Kapikian. 1999. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 17:2715-2725[CrossRef][Medline]. |
| 3. | Cunliffe, N. A., J. S. Gondwe, R. L. Broadhead, M. E. Molyneux, P. A. Woods, J. S. Bresee, R. I. Glass, J. R. Gentsch, and C. A. Hart. 1999. Rotavirus G and P types in children with acute diarrhea in Blantyre, Malawi, from 1997 to 1998: predominance of novel P[6]G8 strains. J. Med. Virol. 57:308-312[CrossRef][Medline]. |
| 4. |
Gentsch, J. R.,
R. I. Glass,
P. Woods,
V. Gouvea,
M. Gorziglia,
J. Flores,
B. K. Das, and M. K. Bhan.
1992.
Identification of group A rotavirus gene 4 types by polymerase chain reaction.
J. Clin. Microbiol.
30:1365-1373 |
| 5. |
Gouvea, V.,
R. I. Glass,
P. Woods,
K. Taniguchi,
H. F. Clark,
B. Forrester, and Z. Y. Fang.
1990.
Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens.
J. Clin. Microbiol.
28:276-282 |
| 6. | Kirkwood, C., P. J. Masendycz, and B. S. Coulson. 1993. Characteristics and location of cross-reactive and serotype-specific neutralization sites on VP7 of human G type 9 rotaviruses. Virology 196:79-88[CrossRef][Medline]. |
| 7. | Parashar, U. D., J. S. Bresee, J. R. Gentsch, and R. I. Glass. 1998. Rotavirus. Emerg. Infect. Dis. 4:561-570[Medline]. |
| 8. |
Ramachandran, M.,
J. R. Gentsch,
U. D. Parashar,
S. Jin,
P. A. Woods,
J. L. Holmes,
C. D. Kirkwood,
R. F. Bishop,
H. B. Greenberg,
S. Urasawa,
G. Gerna,
B. S. Coulson,
K. Taniguchi,
J. S. Bresee, and R. I. Glass.
1998.
Detection and characterization of novel rotavirus strains in the United States.
J. Clin. Microbiol.
36:3223-3229 |
| 9. | Ramachandran, M., B. K. Das, A. Vij, R. Kumar, S. S. Bhambal, N. Kesari, H. Rawat, L. Bahl, S. Thakur, P. A. Woods, R. I. Glass, M. K. Bhan, and J. R. Gentsch. 1996. Unusual diversity of human rotavirus G and P genotypes in India. J. Clin. Microbiol. 34:436-439[Abstract]. |
| 10. |
Unicomb, L. E.,
G. Podder,
J. R. Gentsch,
P. A. Woods,
K. Z. Hasan,
A. S. Faruque,
M. J. Albert, and R. I. Glass.
1999.
Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995.
J. Clin. Microbiol.
37:1885-1891 |
|
Enzo A. Palombo* | |||||
|
Paul J. Masendycz Helen C. Bugg Nada Bogdanovic-Sakran Graeme L. Barnes Ruth F. Bishop National Rotavirus Reference Centre Department of Gastroenterology and Clinical Nutrition Royal Children's Hospital Flemington Road Parkville, Victoria 3052, Australia |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»